Abstract
Objective The risk/benefit profiles of anti-coagulant or anti-platelet agents in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF) remained unclear. We aimed to investigate the stroke risks in these patients with or without anti-coagulant/anti-platelet therapy by using our national database. Method By using our national health insurance ESRD claim database, we searched patients with AF, more than 18 years old and without prior history of ischemic stroke. Medication information as well as the events of ischemic stroke, hemorrhagic stroke, and transient ischemic accident during follow-up were identified from the database. Propensity score method was used to match all the potential confounders between patients with and without anti-platelets/warfarin treatment. Result A total of 134,410 ESRD patients were identified in the database. Among them, patients with non-valvular AF, over 18 years old, without prior history of ischemic stroke and received monotherapy with anti-platelets (1622) or warfarin (294) served as case groups while patients (2983) without taking any anti-platelets and warfarin served as control groups. The incidences of ischemic stroke or transient ischemic attack (TIA) were not different among the control (6.6%), anti-platelet (6.2%) and warfarin (5.1%) groups in a follow-up period of approximately 4 years. The results remained unchanged after propensity match. Cox-regression analyses also showed no beneficial effect of anti-platelet or warfarin therapy in overall and any subgroups. Conclusion In this nationwide cohort analyses, we found that anti-platelet or warfarin treatment could not lower the risk of ischemic stroke in patients with ESRD.
| Original language | English |
|---|---|
| Pages (from-to) | 1008-1011 |
| Number of pages | 4 |
| Journal | International Journal of Cardiology |
| Volume | 177 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Atrial fibrillation
- End-stage renal disease
- Stroke
- Warfarin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation - A nation-wide database analyses. / Chen, Jien Jiun; Lin, Lian Yu; Yang, Yao Hsu; Hwang, Juey Jen; Chen, Pau Chung; Lin, Jiunn Lee.
In: International Journal of Cardiology, Vol. 177, No. 3, 01.01.2014, p. 1008-1011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation - A nation-wide database analyses
AU - Chen, Jien Jiun
AU - Lin, Lian Yu
AU - Yang, Yao Hsu
AU - Hwang, Juey Jen
AU - Chen, Pau Chung
AU - Lin, Jiunn Lee
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Objective The risk/benefit profiles of anti-coagulant or anti-platelet agents in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF) remained unclear. We aimed to investigate the stroke risks in these patients with or without anti-coagulant/anti-platelet therapy by using our national database. Method By using our national health insurance ESRD claim database, we searched patients with AF, more than 18 years old and without prior history of ischemic stroke. Medication information as well as the events of ischemic stroke, hemorrhagic stroke, and transient ischemic accident during follow-up were identified from the database. Propensity score method was used to match all the potential confounders between patients with and without anti-platelets/warfarin treatment. Result A total of 134,410 ESRD patients were identified in the database. Among them, patients with non-valvular AF, over 18 years old, without prior history of ischemic stroke and received monotherapy with anti-platelets (1622) or warfarin (294) served as case groups while patients (2983) without taking any anti-platelets and warfarin served as control groups. The incidences of ischemic stroke or transient ischemic attack (TIA) were not different among the control (6.6%), anti-platelet (6.2%) and warfarin (5.1%) groups in a follow-up period of approximately 4 years. The results remained unchanged after propensity match. Cox-regression analyses also showed no beneficial effect of anti-platelet or warfarin therapy in overall and any subgroups. Conclusion In this nationwide cohort analyses, we found that anti-platelet or warfarin treatment could not lower the risk of ischemic stroke in patients with ESRD.
AB - Objective The risk/benefit profiles of anti-coagulant or anti-platelet agents in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF) remained unclear. We aimed to investigate the stroke risks in these patients with or without anti-coagulant/anti-platelet therapy by using our national database. Method By using our national health insurance ESRD claim database, we searched patients with AF, more than 18 years old and without prior history of ischemic stroke. Medication information as well as the events of ischemic stroke, hemorrhagic stroke, and transient ischemic accident during follow-up were identified from the database. Propensity score method was used to match all the potential confounders between patients with and without anti-platelets/warfarin treatment. Result A total of 134,410 ESRD patients were identified in the database. Among them, patients with non-valvular AF, over 18 years old, without prior history of ischemic stroke and received monotherapy with anti-platelets (1622) or warfarin (294) served as case groups while patients (2983) without taking any anti-platelets and warfarin served as control groups. The incidences of ischemic stroke or transient ischemic attack (TIA) were not different among the control (6.6%), anti-platelet (6.2%) and warfarin (5.1%) groups in a follow-up period of approximately 4 years. The results remained unchanged after propensity match. Cox-regression analyses also showed no beneficial effect of anti-platelet or warfarin therapy in overall and any subgroups. Conclusion In this nationwide cohort analyses, we found that anti-platelet or warfarin treatment could not lower the risk of ischemic stroke in patients with ESRD.
KW - Atrial fibrillation
KW - End-stage renal disease
KW - Stroke
KW - Warfarin
KW - Atrial fibrillation
KW - End-stage renal disease
KW - Stroke
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=84920028036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920028036&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2014.09.140
DO - 10.1016/j.ijcard.2014.09.140
M3 - Article
VL - 177
SP - 1008
EP - 1011
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 3
ER -